PL2723367T3 - Koagoniści receptora glukagonu/GLP-1 - Google Patents

Koagoniści receptora glukagonu/GLP-1

Info

Publication number: PL2723367T3
Authority: PL; Poland
Prior art keywords: glp; glucagon; agonists; receptor
Prior art date: 2011-06-22

Application number

PL12802005T

Other languages

English (en)

Inventor

Richard D Dimarchi

David L Smiley

Original Assignee

Univ Indiana Res & Tech Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-06-22

Filing date

2012-06-12

Publication date

2017-10-31

2012-06-12 Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp

2017-10-31 Publication of PL2723367T3 publication Critical patent/PL2723367T3/pl

Links

102000051325 Glucagon Human genes 0.000 title 1
108010063919 Glucagon Receptors Proteins 0.000 title 1
108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 title 1
102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 title 1
239000000556 agonist Substances 0.000 title 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
229960004666 glucagon Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/605—Glucagons
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Diabetes (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Obesity (AREA)
Zoology (AREA)
Urology & Nephrology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Microbiology (AREA)
Toxicology (AREA)
Physics & Mathematics (AREA)
General Physics & Mathematics (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Food Science & Technology (AREA)
Pathology (AREA)

PL12802005T 2011-06-22 2012-06-12 Koagoniści receptora glukagonu/GLP-1 PL2723367T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201161500027P	2011-06-22	2011-06-22
US201161547360P	2011-10-14	2011-10-14
EP12802005.4A EP2723367B1 (en)	2011-06-22	2012-06-12	Glucagon/glp-1 receptor co-agonists
PCT/US2012/042084 WO2012177443A2 (en)	2011-06-22	2012-06-12	Glucagon/glp-1 receptor co-agonists

Publications (1)

Publication Number	Publication Date
PL2723367T3 true PL2723367T3 (pl)	2017-10-31

Family

ID=47362408

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL12802005T PL2723367T3 (pl)	2011-06-22	2012-06-12	Koagoniści receptora glukagonu/GLP-1

Country Status (34)

Country	Link
US (5)	US9156902B2 (pl)
EP (1)	EP2723367B1 (pl)
JP (1)	JP6179864B2 (pl)
KR (1)	KR101972617B1 (pl)
CN (1)	CN103857408B (pl)
AR (1)	AR086998A1 (pl)
AU (1)	AU2012273364B2 (pl)
CA (1)	CA2839686C (pl)
CL (1)	CL2013003688A1 (pl)
CO (1)	CO6821895A2 (pl)
CY (1)	CY1119577T1 (pl)
DK (1)	DK2723367T3 (pl)
DO (1)	DOP2013000310A (pl)
EA (1)	EA031230B1 (pl)
EC (1)	ECSP13013097A (pl)
ES (1)	ES2636445T3 (pl)
GE (1)	GEP20176629B (pl)
GT (1)	GT201300319A (pl)
HR (1)	HRP20170890T1 (pl)
HU (1)	HUE035776T2 (pl)
IL (1)	IL230061B (pl)
LT (1)	LT2723367T (pl)
ME (1)	ME02816B (pl)
MX (1)	MX347703B (pl)
NI (1)	NI201300143A (pl)
PE (1)	PE20140724A1 (pl)
PH (1)	PH12013502671A1 (pl)
PL (1)	PL2723367T3 (pl)
PT (1)	PT2723367T (pl)
RS (1)	RS56173B1 (pl)
SI (1)	SI2723367T1 (pl)
TW (1)	TWI554518B (pl)
WO (1)	WO2012177443A2 (pl)
ZA (1)	ZA201309626B (pl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2676673B1 (en)	2008-06-17	2016-11-16	Indiana University Research and Technology Corporation	Glucagon/glp-1 receptor co-agonists
IN2012DN00377A (pl)	2009-06-16	2015-08-21	Univ Indiana Res & Tech Corp
SI2723367T1 (sl)	2011-06-22	2017-08-31	Indiana University Research And Technology Corporation	Koagonisti receptorja glukanona/GLP-1
AR088161A1 (es)	2011-09-23	2014-05-14	Novo Nordisk As	Analogos de glucagon
BR112014031671A2 (pt) *	2012-06-21	2018-08-07	Hoffmann La Roche	análogos de glucagon exibindo atividade de receptor gip
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
LT2934567T (lt)	2012-12-21	2018-09-10	Sanofi	Eksendino-4 dariniai kaip dvigubi glp1/gip arba trigubi glp1/gip/gliukagono agonistai
MX362275B (es)	2013-04-18	2019-01-10	Novo Nordisk As	Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico.
TW201609797A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／升糖素受體促效劑
EP3080154B1 (en)	2013-12-13	2018-02-07	Sanofi	Dual glp-1/gip receptor agonists
EP3080150B1 (en)	2013-12-13	2018-08-01	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086730A1 (en)	2013-12-13	2015-06-18	Sanofi	Non-acylated exendin-4 peptide analogues
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
CN106536547A (zh)	2014-06-04	2017-03-22	诺和诺德股份有限公司	用于医疗用途的glp‑1/胰高血糖素受体共激动剂
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
CA2964379C (en)	2014-10-24	2023-08-15	Merck Sharp & Dohme Corp.	Co-agonists of the glucagon and glp-1 receptors
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198628A1 (en)	2015-06-12	2016-12-15	Sanofi	Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
WO2016198624A1 (en)	2015-06-12	2016-12-15	Sanofi	Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
WO2017062334A1 (en)	2015-10-05	2017-04-13	Merck Sharp & Dohme Corp.	Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
TWI622596B (zh)	2015-10-26	2018-05-01	美國禮來大藥廠	升糖素受體促效劑
EP3377521A4 (en) *	2015-10-27	2019-05-01	Merck Sharp & Dohme Corp.	LONG-ACTING CO AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS
US10493125B2 (en)	2015-12-09	2019-12-03	Merck Sharp & Dohme Corp.	Co-agonists of the glucagon and GLP-1 receptors
CA3009506A1 (en)	2015-12-23	2017-06-29	The Johns Hopkins University	Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions
CN113546159B (zh) *	2015-12-29	2023-09-08	派格生物医药(苏州)股份有限公司	包含glp-1受体激动剂和胰高血糖素受体激动剂的组合物及其用途
EP3448417B1 (en) *	2016-04-26	2025-11-12	Merck Sharp & Dohme LLC	Insulin dimer-incretin conjugates
AU2017260003B2 (en) *	2016-05-06	2019-12-05	Astrazeneca Ab	GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof
AU2018293467B2 (en)	2017-06-29	2020-11-05	ImmuPharma Biotech SAS	Pro-drug peptide with improved pharmaceutical properties
EP3700550A4 (en)	2017-09-25	2022-02-23	Merck Sharp & Dohme Corp.	LONG-ACTING CO-AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS
CA3081956A1 (en) *	2017-11-08	2019-05-16	Ionis Pharmaceuticals, Inc	Glp-1 receptor ligand moiety conjugated oligonucleotides and uses thereof
CN109836488B (zh) *	2017-11-24	2022-08-23	浙江道尔生物科技有限公司	一种治疗代谢疾病的胰高血糖素类似物
TWI705820B (zh)	2018-06-22	2020-10-01	美商美國禮來大藥廠	Gip/glp1促效劑組合物
US12441776B2 (en)	2018-11-30	2025-10-14	Eirgen Pharma Ltd.	Oxyntomodulin peptide analog formulations
WO2020148317A1 (en)	2019-01-18	2020-07-23	Ureka Sarl	Peptide-oligourea hybrid compounds
US11471512B2 (en)	2019-03-01	2022-10-18	Merck Sharp & Dohme Llc	Pharmaceutical compositions of a peptide
US12252582B2 (en)	2019-08-29	2025-03-18	University Of Delaware	Biofunctional thiophene monomers and polymers thereof for electronic biomedical devices
EP3842060A1 (en) *	2019-12-23	2021-06-30	Merck Sharp & Dohme Corp.	Stapled lactam co-agonists of the glucagon and glp-1 receptors
EP3842449A1 (en)	2019-12-23	2021-06-30	Merck Sharp & Dohme Corp.	Stapled olefin co-agonists of the glucagon and glp-1 receptors
EP3842061A1 (en) *	2019-12-23	2021-06-30	Merck Sharp & Dohme Corp.	Stapled triazole co-agonists of the glucagon and glp-1 receptors
CN115322794B (zh) *	2020-01-11	2025-09-19	北京质肽生物医药科技有限公司	Glp-1和fgf21的融合蛋白的缀合物
CN112409460B (zh) *	2020-11-27	2022-02-01	江苏师范大学	一类glp-1/胰高血糖素受体双重激动剂及其应用
EP4262873A4 (en) *	2020-12-16	2024-12-11	The Chinese University of Hong Kong	A method for reversing aging brain functional decline
JP2025535379A (ja) *	2022-10-19	2025-10-24	イーライリリーアンドカンパニー	保存されたｇｉｐ／ｇｌｐアゴニスト組成物
WO2024252366A1 (en) *	2023-06-09	2024-12-12	Sun Pharmaceutical Industries Limited	Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists
US12303604B1 (en)	2024-10-16	2025-05-20	Currax Pharmaceuticals Llc	Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4450150A (en)	1973-05-17	1984-05-22	Arthur D. Little, Inc.	Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4275152A (en)	1977-02-03	1981-06-23	Eastman Kodak Company	Hydrolysis of protein-bound cholesterol esters
PT83613B (en)	1985-10-28	1988-11-21	Lilly Co Eli	Process for the selective chemical removal of a protein amino-terminal residue
JPS63502716A (ja)	1986-03-07	1988-10-13	マサチューセッツ・インステチュート・オブ・テクノロジー	糖タンパク安定性の強化方法
IN165717B (pl)	1986-08-07	1989-12-23	Battelle Memorial Institute
WO1990009395A1 (en)	1989-02-17	1990-08-23	Coselco Mimotopes Pty. Ltd.	Method for the use and synthesis of peptides
US5545618A (en)	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
CA2073856C (en)	1990-01-24	2002-12-03	Douglas I. Buckley	Glp-1 analogs useful for diabetes treatment
CA2024855C (en)	1990-09-07	1997-12-09	Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) Ltee	Process and intermediates for producing glucagon
JPH04145099A (ja)	1990-10-05	1992-05-19	Sanwa Kagaku Kenkyusho Co Ltd	Ｇｉｐ様活性を有するポリペプチド誘導体及びその用途
US5510459A (en)	1991-01-17	1996-04-23	Zymogenetics, Inc.	Glucagon antagonists
JP3266311B2 (ja)	1991-05-02	2002-03-18	生化学工業株式会社	新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
US5359030A (en)	1993-05-10	1994-10-25	Protein Delivery, Inc.	Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5480867A (en)	1993-12-29	1996-01-02	The Rockefeller University	Glucagon analogs with serine replacements
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5869602A (en)	1995-03-17	1999-02-09	Novo Nordisk A/S	Peptide derivatives
DE19530865A1 (de)	1995-08-22	1997-02-27	Michael Dr Med Nauck	Wirkstoff sowie Mittel zur parenteralen Ernährung
CA2243718A1 (en)	1996-02-06	1997-08-14	Eli Lilly And Company	Diabetes therapy
ATE316100T1 (de)	1996-06-05	2006-02-15	Roche Diagnostics Gmbh	Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
IL128828A0 (en)	1996-09-09	2000-01-31	Zealand Pharmaceuticals As	Peptide prodrugs containing an alpha-hydroxy acid linker
UA65549C2 (uk)	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
AU5518798A (en)	1996-12-03	1998-06-29	Trustees Of Boston University	Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
EP1053752A1 (en)	1998-02-10	2000-11-22	Yoshitomi Pharmaceutical Industries, Ltd.	Preparations with controlled release
IL138214A0 (en)	1998-03-09	2001-10-31	Zealand Pharmaceuticals As	Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
DE19828113A1 (de)	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
US20030236190A1 (en)	1998-09-02	2003-12-25	Renuka Pillutla	Isulin and IGF-1 receptor agonists and antagonists
US6410508B1 (en)	1998-10-07	2002-06-25	Med College Georgia Res Inst	Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
GB2344287A (en)	1998-12-03	2000-06-07	Ferring Bv	Controlled release pharmaceutical formulation
PL202367B1 (pl)	1998-12-07	2009-06-30	Sod Conseils Rech Applic	Związki stanowiące analogi GLP-1, kompozycje zawierające te związki oraz zastosowanie tych związków
EP1147094A1 (en) *	1999-01-15	2001-10-24	Novo Nordisk A/S	Non-peptide glp-1 agonists
WO2000058360A2 (en)	1999-03-29	2000-10-05	Uutech Limited	Analogs of gastric inhibitory peptide and their use for treatment of diabetes
GB0404124D0 (en)	2004-02-25	2004-03-31	Univ Ulster	Antagonists of GIP
SI1180121T1 (en)	1999-05-17	2004-04-30	Conjuchem, Inc.	Long lasting insulinotropic peptides
WO2001081919A2 (en)	2000-04-27	2001-11-01	Bionebraska, Inc.	Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose
US6677136B2 (en)	2000-05-03	2004-01-13	Amgen Inc.	Glucagon antagonists
JP2004503565A (ja)	2000-06-14	2004-02-05	サイトヴァックス・バイオテクノロジーズ・インコーポレーテッド	構造特異的ペプチドを生産するためのコイルドコイル構造的骨格の使用
MXPA02012203A (es)	2000-06-16	2003-06-06	Lilly Co Eli	Analogos de peptido 1 tipo glucagon.
SE525948C2 (sv)	2000-06-28	2005-05-31	Modig Technical Consulting Ab	Fleroperationsmaskin
JP2004509079A (ja)	2000-08-02	2004-03-25	セラテクノロジーズ・インコーポレーテッド	効力が増大した修飾生体ペプチド
US6528520B2 (en)	2000-08-15	2003-03-04	Cpd, Llc	Method of treating the syndrome of coronary heart disease risk factors in humans
US6262062B1 (en)	2000-08-15	2001-07-17	Cpd, Llc	Method of treating the syndrome of coronary heart disease risk factors in humans
US20020045572A1 (en)	2000-08-15	2002-04-18	Cpd, Llc	Method of treating the syndrome of type 2 diabetes in humans
US6846831B2 (en)	2000-08-15	2005-01-25	Cpd, Llc	Method of treating the syndrome of lipodystrophy
US7052686B2 (en)	2000-09-29	2006-05-30	Schering Corporation	Pegylated interleukin-10
US7199217B2 (en)	2000-12-13	2007-04-03	Eli Lilly And Company	Amidated glucagon-like peptide-1
EP2275117B1 (en)	2001-07-31	2016-10-26	The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services	GLP-1, exendin-4, peptide analogs and uses thereof
EP1572885A2 (en)	2001-08-08	2005-09-14	Genzyme Corporation	Methods for treating diabetes and other blood sugar disorders
EP1432430A4 (en)	2001-08-28	2006-05-10	Lilly Co Eli	PREMIXTURES OF GLP-1 AND BASALINSULIN
GB0121709D0 (en)	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
AR036711A1 (es)	2001-10-05	2004-09-29	Bayer Corp	Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
US7041646B2 (en)	2001-10-05	2006-05-09	Bayer Pharmaceuticals Corporation	Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
AU2002348469B2 (en)	2001-10-18	2008-03-13	Bristol-Myers Squibb Company	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7179788B2 (en)	2001-10-19	2007-02-20	Eli Lilly And Company	Biphasic mixtures of GLP-1 and insulin
WO2003059378A2 (en)	2001-12-29	2003-07-24	Novo Nordisk A/S	Combined use of a glp-1 compound and another drug for treating dyslipidemia
WO2003058203A2 (en)	2002-01-08	2003-07-17	Eli Lilly And Company	Extended glucagon-like peptide-1 analogs
US20030232761A1 (en)	2002-03-28	2003-12-18	Hinke Simon A.	Novel analogues of glucose-dependent insulinotropic polypeptide
EP1575490A4 (en)	2002-06-04	2007-08-08	Lilly Co Eli	MODIFIED ANALOGUES OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1)
AU2003237933A1 (en)	2002-06-11	2003-12-22	Cellartis Ab	Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity
US20040029805A1 (en)	2002-06-15	2004-02-12	Wolfe M. Michael	Prevention and treatment of nonalcoholic fatty liver disease (NAFLD) by antagonism of the receptor to glucose-dependent insulinotropic polypeptide (GIP)
EP1539210A4 (en)	2002-09-06	2006-06-07	Bayer Pharmaceuticals Corp	GLP-1 RECEPTOR MODIFIED AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE
ATE458534T1 (de)	2002-10-04	2010-03-15	Microchips Inc	Medizinische vorrichtung zur gesteuerten arzneimittelverabreichung sowie herzüberwachung und/oder herzstimulation
US7192922B2 (en)	2002-11-19	2007-03-20	Allegheny-Singer Research Institute	Method of treating left ventricular dysfunction
AU2004204494B2 (en)	2003-01-09	2011-09-29	Macrogenics, Inc.	Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2004067548A2 (en)	2003-01-31	2004-08-12	Theratechnologies Inc.	Chemically modified metabolites of regulatory peptides and methods of producing and using same
EP1626981A4 (en)	2003-03-04	2006-11-22	Biorexis Pharmaceutical Corp	PROTEINS PROTECTED AGAINST DIPEPTIDYLPEPTIDASE
PL1605897T3 (pl)	2003-03-19	2012-12-31	Lilly Co Eli	Związki będące połączeniem GLP-1 z poli(glikolem etylenowym)
EP1620118B1 (en)	2003-04-08	2014-06-18	Yeda Research And Development Co., Ltd.	Reversible pegylated drugs
TWI353991B (en)	2003-05-06	2011-12-11	Syntonix Pharmaceuticals Inc	Immunoglobulin chimeric monomer-dimer hybrids
WO2004103390A2 (en)	2003-05-15	2004-12-02	Trustees Of Tufts College	Stable analogs of peptide and polypeptide therapeutics
WO2004105781A2 (en)	2003-06-03	2004-12-09	Novo Nordisk A/S	Stabilized pharmaceutical peptide compositions
JP2007524592A (ja)	2003-06-03	2007-08-30	ノボ・ノルデイスク・エー／エス	安定化された薬学的ペプチド組成物
PL1641823T3 (pl)	2003-06-12	2012-02-29	Lilly Co Eli	Białka fuzyjne analogu GLP-1
WO2004111078A2 (en)	2003-06-18	2004-12-23	Theratechnologies Inc.	Compounds that modulate the glucagon response and uses thereof
WO2005027978A2 (en)	2003-09-19	2005-03-31	Novo Nordisk A/S	Albumin-binding derivatives of therapeutic peptides
US7364875B2 (en)	2003-10-30	2008-04-29	Cresent Innovations, Inc.	Method for producing medical and commercial grade poly-gamma-glutamic acid of high molecular weight
WO2005058954A1 (en)	2003-12-18	2005-06-30	Novo Nordisk A/S	Novel glp-1 compounds
US20060286129A1 (en)	2003-12-19	2006-12-21	Emisphere Technologies, Inc.	Oral GLP-1 formulations
US20080318837A1 (en)	2003-12-26	2008-12-25	Nastech Pharmaceutical Company Inc.	Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US7442682B2 (en)	2004-10-19	2008-10-28	Nitto Denko Corporation	Transepithelial delivery of peptides with incretin hormone activities
AU2006213607A1 (en)	2005-02-11	2006-08-17	Amylin Pharmaceuticals, Llc	GIP analog and hybrid polypeptides with selectable properties
US8263545B2 (en)	2005-02-11	2012-09-11	Amylin Pharmaceuticals, Inc.	GIP analog and hybrid polypeptides with selectable properties
WO2006097536A2 (en)	2005-03-18	2006-09-21	Novo Nordisk A/S	Dimeric peptide agonists of the glp-1 receptor
WO2006121904A1 (en)	2005-05-06	2006-11-16	Bayer Pharmaceuticals Corporation	Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use
CN101166545B (zh)	2005-05-13	2011-06-15	伊莱利利公司	Glp-1聚乙二醇化的化合物
PT1891105E (pt)	2005-06-13	2012-06-27	Imp Innovations Ltd	Análogos de oxintomodulina e seus efeitos sobre o comportamento da alimentação
AU2006279680B2 (en)	2005-08-11	2012-12-06	Amylin Pharmaceuticals, Llc	Hybrid polypeptides with selectable properties
AU2006289259A1 (en)	2005-09-08	2007-03-15	Uutech Limited	Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
CA2622069A1 (en)	2005-09-08	2007-03-15	Uutech Limited	Treatment of diabetes related obesity
US7846445B2 (en)	2005-09-27	2010-12-07	Amunix Operating, Inc.	Methods for production of unstructured recombinant polymers and uses thereof
CN101534846B (zh)	2005-11-07	2014-11-05	印第安纳大学研究及科技有限公司	显示生理学溶解性和稳定性的胰高血糖素类似物
US7928058B2 (en)	2006-02-22	2011-04-19	Merck Sharp & Dohme Corp.	Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition
EP1996224B1 (en)	2006-03-15	2012-11-07	Novo Nordisk A/S	Mixtures of amylin and insulin
WO2007109354A2 (en)	2006-03-21	2007-09-27	Amylin Pharmaceuticals, Inc.	Peptide-peptidase inhibitor conjugates and methods of using same
MX2008013304A (es)	2006-04-20	2008-10-27	Amgen Inc	Compuestos de peptido 1 tipo glucagon.
US8475972B2 (en)	2006-05-01	2013-07-02	Honda Motor Co., Ltd.	Fuel cell
MX2008014418A (es)	2006-05-15	2008-11-27	Wisconsin Alumni Res Found	Administracion pulmonar de la 1 alfa, 25-dihidroxivitamina d3 y co-administracion de la homona paratiroidea o calcitonina.
FR2902092B1 (fr)	2006-06-07	2008-09-05	Sapelem Soc Par Actions Simpli	Appareil de manutention de charge
WO2008022015A2 (en)	2006-08-11	2008-02-21	Trustees Of Tufts College	Retro-inverso incretin analogues, and methods of use thereof
CA2660835A1 (en)	2006-08-17	2008-02-21	Amylin Pharmaceuticals, Inc.	Dpp-iv resistant gip hybrid polypeptides with selectable propperties
EP2057189B1 (en)	2006-08-25	2013-03-06	Novo Nordisk A/S	Acylated exendin-4 compounds
CA2663083A1 (en)	2006-09-08	2008-03-13	Ambrx, Inc.	Modified human plasma polypeptide or fc scaffolds and their uses
EP2102355B1 (en)	2006-12-14	2016-03-02	Bolder Biotechnology, Inc.	Long acting proteins and peptides and methods of making and using the same
JP5890085B2 (ja)	2007-01-05	2016-03-22	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	生理学的ｐＨの緩衝液中で向上した溶解度を示すグルカゴン類縁体
US8454971B2 (en)	2007-02-15	2013-06-04	Indiana University Research And Technology Corporation	Glucagon/GLP-1 receptor co-agonists
CA2683698C (en)	2007-04-19	2013-09-10	Hyun Hee Kwak	A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
DK2158214T3 (da)	2007-06-15	2011-12-05	Zealand Pharma As	Glukagonanaloger
CN103298935A (zh)	2007-08-15	2013-09-11	阿穆尼克斯公司	用于改善生物活性多肽性能的组合物和方法
US8895694B2 (en)	2007-09-05	2014-11-25	Novo Nordisk A/S	Glucagon-Like Peptide-1 derivatives and their pharmaceutical use
EP2190873B1 (en)	2007-09-05	2015-07-22	Novo Nordisk A/S	Truncated glp-1 derivatives and their therapeutical use
EP2650006A1 (en)	2007-09-07	2013-10-16	Ipsen Pharma S.A.S.	Analogues of exendin-4 and exendin-3
EP2036923A1 (en)	2007-09-11	2009-03-18	Novo Nordisk A/S	Improved derivates of amylin
CN101854948A (zh)	2007-09-11	2010-10-06	诺沃-诺迪斯克有限公司	含有胰岛淀粉样多肽类和长效胰岛素的合剂
EP2036539A1 (en)	2007-09-11	2009-03-18	Novo Nordisk A/S	Stable formulations of amylin and its analogues
EP2214691B1 (en)	2007-10-30	2015-09-30	Indiana University Research and Technology Corporation	Compounds exhibiting glucagon antagonist and glp-1 agonist activity
AU2008318986B2 (en)	2007-10-30	2014-12-04	Indiana University Research And Technology Corporation	Glucagon antagonists
WO2009059278A1 (en)	2007-11-02	2009-05-07	Centocor, Inc.	Semi-synthetic glp-1 peptide-fc fusion constructs, methods and uses
WO2009099763A1 (en)	2008-01-30	2009-08-13	Indiana University Research And Technology Corporation	Ester-based peptide prodrugs
JP5588354B2 (ja)	2008-02-01	2014-09-10	アセンディスファーマエー／エス	自己切断可能なリンカーを含むプロドラッグ
AR072159A1 (es)	2008-06-17	2010-08-11	Univ Indiana Res & Tech Corp	Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad
WO2009155257A1 (en)	2008-06-17	2009-12-23	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
EP2676673B1 (en)	2008-06-17	2016-11-16	Indiana University Research and Technology Corporation	Glucagon/glp-1 receptor co-agonists
CA2744558A1 (en)	2008-12-19	2010-07-15	Indiana University Research And Technology Corporation	Amide-based insulin prodrugs
CN102300580A (zh)	2008-12-19	2011-12-28	印第安纳大学研究及科技有限公司	二肽连接的药剂
US20110245164A1 (en)	2008-12-19	2011-10-06	Indiana University Research And Technology Corporation	Yl-based insulin-like growth factors exhibiting high activity at the insulin receptor
WO2010071807A1 (en)	2008-12-19	2010-06-24	Indiana University Research And Technology Corporation	Amide based glucagon superfamily peptide prodrugs
WO2010096052A1 (en)	2009-02-19	2010-08-26	Merck Sharp & Dohme Corp.	Oxyntomodulin analogs
IN2012DN00377A (pl) *	2009-06-16	2015-08-21	Univ Indiana Res & Tech Corp
EP2512503A4 (en)	2009-12-18	2013-08-21	Univ Indiana Res & Tech Corp	COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
AR079345A1 (es)	2009-12-22	2012-01-18	Lilly Co Eli	Analogo peptidico de oxintomodulina
AR079344A1 (es)	2009-12-22	2012-01-18	Lilly Co Eli	Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
IN2012DN06437A (pl)	2010-01-27	2015-10-09	Univ Indiana Res & Tech Corp
AR080592A1 (es)	2010-03-26	2012-04-18	Lilly Co Eli	Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
WO2011143208A1 (en)	2010-05-13	2011-11-17	Indiana University Research And Technology Corporation	Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
KR20130062931A (ko)	2010-05-13	2013-06-13	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	핵 호르몬 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
RU2013102991A (ru)	2010-06-24	2014-08-10	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	Связанные с дипептидом лекарственные средства
US8778872B2 (en)	2010-06-24	2014-07-15	Indiana University Research And Technology Corporation	Amide based glucagon superfamily peptide prodrugs
WO2011163473A1 (en)	2010-06-25	2011-12-29	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
PH12013501215A1 (en)	2010-12-22	2013-11-18	Univ Indiana Res & Tech Corp	Glucagon analogs exhibiting gip receptor activity
JP2012194860A (ja)	2011-03-17	2012-10-11	Murata Mach Ltd	走行車
CN103748109A (zh)	2011-06-22	2014-04-23	印第安纳大学研究及科技有限公司	胰高血糖素/glp-1受体共同激动剂
SI2723367T1 (sl)	2011-06-22	2017-08-31	Indiana University Research And Technology Corporation	Koagonisti receptorja glukanona/GLP-1
RU2014117678A (ru)	2011-11-17	2015-12-27	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью
JP6311708B2 (ja)	2012-06-21	2018-04-18	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	Ｇｉｐ受容体活性を示すグルカゴンアナローグ
TW201402611A (zh)	2012-06-21	2014-01-16	Univ Indiana Res & Tech Corp	具有改變之ｆｃ效應子功能之腸促胰島素受體配體多肽ｆｃ區融合多肽及結合物

2012
- 2012-06-12 SI SI201230998T patent/SI2723367T1/sl unknown
- 2012-06-12 AU AU2012273364A patent/AU2012273364B2/en not_active Ceased
- 2012-06-12 PE PE2013002863A patent/PE20140724A1/es active IP Right Grant
- 2012-06-12 ME MEP-2017-169A patent/ME02816B/me unknown
- 2012-06-12 KR KR1020147001701A patent/KR101972617B1/ko not_active Expired - Fee Related
- 2012-06-12 PH PH1/2013/502671A patent/PH12013502671A1/en unknown
- 2012-06-12 CN CN201280037512.4A patent/CN103857408B/zh not_active Expired - Fee Related
- 2012-06-12 US US13/494,484 patent/US9156902B2/en not_active Expired - Fee Related
- 2012-06-12 JP JP2014517014A patent/JP6179864B2/ja not_active Expired - Fee Related
- 2012-06-12 WO PCT/US2012/042084 patent/WO2012177443A2/en not_active Ceased
- 2012-06-12 PL PL12802005T patent/PL2723367T3/pl unknown
- 2012-06-12 EP EP12802005.4A patent/EP2723367B1/en active Active
- 2012-06-12 DK DK12802005.4T patent/DK2723367T3/en active
- 2012-06-12 CA CA2839686A patent/CA2839686C/en not_active Expired - Fee Related
- 2012-06-12 PT PT128020054T patent/PT2723367T/pt unknown
- 2012-06-12 US US14/127,456 patent/US20140221283A1/en not_active Abandoned
- 2012-06-12 MX MX2013015176A patent/MX347703B/es active IP Right Grant
- 2012-06-12 LT LTEP12802005.4T patent/LT2723367T/lt unknown
- 2012-06-12 EA EA201490070A patent/EA031230B1/ru not_active IP Right Cessation
- 2012-06-12 GE GEAP201213355A patent/GEP20176629B/en unknown
- 2012-06-12 HU HUE12802005A patent/HUE035776T2/en unknown
- 2012-06-12 HR HRP20170890TT patent/HRP20170890T1/hr unknown
- 2012-06-12 ES ES12802005.4T patent/ES2636445T3/es active Active
- 2012-06-12 RS RS20170661A patent/RS56173B1/sr unknown
- 2012-06-21 AR ARP120102199A patent/AR086998A1/es not_active Application Discontinuation
- 2012-06-21 TW TW101122300A patent/TWI554518B/zh not_active IP Right Cessation
2013
- 2013-12-19 ZA ZA2013/09626A patent/ZA201309626B/en unknown
- 2013-12-19 IL IL230061A patent/IL230061B/en active IP Right Grant
- 2013-12-20 EC ECSP13013097 patent/ECSP13013097A/es unknown
- 2013-12-20 CL CL2013003688A patent/CL2013003688A1/es unknown
- 2013-12-20 GT GT201300319A patent/GT201300319A/es unknown
- 2013-12-20 NI NI201300143A patent/NI201300143A/es unknown
- 2013-12-20 DO DO2013000310A patent/DOP2013000310A/es unknown
- 2013-12-20 CO CO13297842A patent/CO6821895A2/es not_active Application Discontinuation
2015
- 2015-09-08 US US14/847,646 patent/US9758562B2/en not_active Expired - Fee Related
2017
- 2017-07-27 CY CY20171100802T patent/CY1119577T1/el unknown
- 2017-08-07 US US15/670,200 patent/US10174093B2/en not_active Expired - Fee Related
2019
- 2019-01-07 US US16/241,932 patent/US10730923B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EA031230B1 (ru)	2018-12-28
PH12013502671A1 (en)	2022-04-08
JP2014525901A (ja)	2014-10-02
CN103857408B (zh)	2017-04-12
CO6821895A2 (es)	2013-12-31
US9156902B2 (en)	2015-10-13
CA2839686C (en)	2019-12-24
AU2012273364A1 (en)	2014-01-16
ZA201309626B (en)	2017-09-27
ECSP13013097A (es)	2014-01-31
ME02816B (me)	2018-01-20
ES2636445T3 (es)	2017-10-05
HUE035776T2 (en)	2018-05-28
JP6179864B2 (ja)	2017-08-16
PT2723367T (pt)	2017-08-11
KR101972617B1 (ko)	2019-04-25
US20150376256A1 (en)	2015-12-31
TW201300408A (zh)	2013-01-01
US10174093B2 (en)	2019-01-08
EP2723367A2 (en)	2014-04-30
SI2723367T1 (sl)	2017-08-31
US20120329708A1 (en)	2012-12-27
US10730923B2 (en)	2020-08-04
PE20140724A1 (es)	2014-07-10
TWI554518B (zh)	2016-10-21
AU2012273364B2 (en)	2017-06-08
EA201490070A1 (ru)	2014-05-30
DOP2013000310A (es)	2014-07-15
GT201300319A (es)	2014-11-26
WO2012177443A2 (en)	2012-12-27
NI201300143A (es)	2014-06-06
HRP20170890T1 (hr)	2017-09-08
MX347703B (es)	2017-05-09
IL230061B (en)	2020-01-30
US20190127433A1 (en)	2019-05-02
LT2723367T (lt)	2017-08-25
US9758562B2 (en)	2017-09-12
RS56173B1 (sr)	2017-11-30
WO2012177443A3 (en)	2013-04-25
CY1119577T1 (el)	2018-03-07
US20140221283A1 (en)	2014-08-07
DK2723367T3 (en)	2017-07-17
GEP20176629B (en)	2017-02-27
AR086998A1 (es)	2014-02-05
CL2013003688A1 (es)	2014-07-25
MX2013015176A (es)	2014-03-21
NZ619447A (en)	2016-04-29
KR20140043792A (ko)	2014-04-10
CN103857408A (zh)	2014-06-11
EP2723367B1 (en)	2017-05-03
CA2839686A1 (en)	2012-12-27
EP2723367A4 (en)	2015-05-06
US20170349642A1 (en)	2017-12-07

Publication	Publication Date	Title
IL230061B (en)	2020-01-30	Glucagon/1–glp receptor co-agonists
AU2012273365A8 (en)	2014-01-30	Glucagon/GLP-1 receptor co-agonists
IL229732A0 (en)	2014-01-30	Long-acting glucagon\1 -glp receptor agonists
AP3338A (en)	2015-07-31	Glucagon receptor modulator
GB2527442B (en)	2016-07-20	Synchronisation mechanism
ZA201307119B (en)	2014-05-28	Double-acylated glp-1 derivatives
IL232800A0 (en)	2014-07-31	Glucagon analog
IL231199A0 (en)	2014-04-30	New analogs of glucagon
IL209750A0 (en)	2011-02-28	Glucagon/glp-1 receptor co-agonists
PT2713722T (pt)	2017-06-27	Novos estabilizadores e moduladores do receptor glp-1
ZA201306514B (en)	2014-05-28	Novel glucagon analogues
GB2505331B (en)	2018-11-07	Downhole Clamping Mechanism
IL228422A0 (en)	2013-12-31	Hormone nuclear protein modulators
PT2714661E (pt)	2016-01-22	Derivados de ácido picolinamido propanóico úteis como antagonistas do recetor de glucagona
GB2492472B (en)	2015-12-16	Connection mechanism
ZA201303950B (en)	2014-07-30	Glucagon receptor modulators
IL230537A0 (en)	2014-03-31	Quinolinyl glucagon receptor modulators
PT2719842E (pt)	2015-12-09	Reforço para utilização estrutural
PL2714647T3 (pl)	2015-09-30	Pochodne bifenylu przydatne jako antagoniści receptora glukagonu
HK1195913A (en)	2014-11-28	Glucagon/glp-1 receptor co-agonists
GB201113354D0 (en)	2011-09-21	Leptin receptor structure
GB201120262D0 (en)	2012-01-04	Simultaneous demultiplexing
ZA201204445B (en)	2013-02-27	Synchronized energiser operation
ZA201206269B (en)	2013-04-24	Pylon